Jasper Therapeutics
JSPR
33 hedge funds and large institutions have $71.2M invested in Jasper Therapeutics in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
18% more funds holding
Funds holding: 28 → 33 (+5)
14% more capital invested
Capital invested by funds: $62.5M → $71.2M (+$8.72M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Longfellow Investment Management
Boston,
Massachusetts
|
+$1.84M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$1.47M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$981K |
| 4 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$908K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$815K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$733K |
| 2 |
JG
Jefferies Group
New York
|
-$340K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$293K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$244K |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$74.9K |
JSPR Hedge Fund Activity: Q2 2020 in Review
33 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2020, worth a combined $71.2M — up 14% from $62.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new JSPR positions and 1 closed out — a net gain of 6 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Longfellow Investment Management, opening a new position worth an estimated $1.84M. The largest seller was Verition Fund Management, cutting an estimated $733K.
- 33 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2020, up from 28 in Q1 2020.
- Funds reported $71.2M of Jasper Therapeutics stock for Q2 2020, up 14% quarter-over-quarter.
- 7 funds opened new Jasper Therapeutics positions in Q2 2020 and 1 closed out, a net change of +6 holders.
- The largest Jasper Therapeutics buyer in Q2 2020 was Longfellow Investment Management, an estimated $1.84M added.
- The largest Jasper Therapeutics seller in Q2 2020 was Verition Fund Management, an estimated $733K sold.
Based on aggregated 13F filings for Q2 2020.